Sienna Cancer Diagnostics (ASX: SDX) has appointed a Brazilian distributor for its breakthrough bladder cancer detection test.
The appointment of Inside Diagnosticos as its exclusive agent selling to pathology labs follows the recent appointments of distributors in Korea and Singapore.
Sienna has the first ever in vitro diagnostic (IVD) for detection of telomerase as an adjunct to urine cytology for assisting the diagnosis of bladder cancer.
CEO Matthew Hoskin said: “Increasing sales through geographical expansion is key to realising the global market opportunity for the hTERT test.
“We expect to enter further markets in the near future.”
Sienna has distributors in place in the US, Denmark, Sweden, Switzerland and China.
In a March investor update Hoskin said the company was also developing its new product pipeline.
Melbourne-based Sienna recently raised $5.2 million from investors in an equity raising.
“This funding has allowed Sienna to progress the assessment of several potential targets for our expansion program.
“This strategy is an important one. We expect to create a pipeline of products that will generate a significant increase in our market opportunity, sustainable revenue and profit growth.”
Picture: Sienna Cancer Diagnostics
Subscribe to our free @AuManufacturing newsletter here.